Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer?
The cartilage oligomeric matrix protein (COMP) and Golgi-protein-73 (GP73) have been proposed as markers of liver fibrosis and hepatocellular carcinoma (HCC). Our aim was to assess the performance of the combination of these markers in diagnosing cirrhosis and predicting HCC development. Sera from 2...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/14/3510 |
| _version_ | 1797527452429320192 |
|---|---|
| author | Nikolaos K. Gatselis Kalliopi Zachou George Giannoulis Stella Gabeta Gary L. Norman George N. Dalekos |
| author_facet | Nikolaos K. Gatselis Kalliopi Zachou George Giannoulis Stella Gabeta Gary L. Norman George N. Dalekos |
| author_sort | Nikolaos K. Gatselis |
| collection | DOAJ |
| description | The cartilage oligomeric matrix protein (COMP) and Golgi-protein-73 (GP73) have been proposed as markers of liver fibrosis and hepatocellular carcinoma (HCC). Our aim was to assess the performance of the combination of these markers in diagnosing cirrhosis and predicting HCC development. Sera from 288 consecutive patients with chronic liver diseases were investigated by using COMP and GP73-ELISAs. Dual positivity for COMP (>15 U/L) and GP73 (>20 units) was observed in 24 (8.3%) patients, while 30 (10.4%) were GP73(+)/COMP(−), 37/288 (12.8%) GP73(−)/COMP(+), and 197 (68.5%) GP73(−)/COMP(−). Positivity for both markers was associated with cirrhosis [23/24 (95.8%) for GP73(+)/COMP(+) vs. 22/30 (73.3%) for GP73(+)/COMP(−) vs. 25/37 (67.6%) for GP73(−)/COMP(+) vs. 46/197 (23.4%) for GP73(−)/COMP(−); <i>P</i> < 0.001]. The combination of GP73, COMP, the aspartate aminotransferase/platelets ratio index, and the Fibrosis-4 score had even higher diagnostic accuracy to detect the presence of cirrhosis [AUC (95% CI): 0.916 (0.878–0.946)] or significant liver fibrosis (METAVIR ≥ F2) [AUC (95% CI): 0.832 (0.768–0.883)] than each marker alone. Kaplan-Meier analysis showed that positivity for both GP73 and COMP was associated with higher rates of HCC development (<i>P</i> < 0.001) and liver-related deaths (<i>P</i> < 0.001) during follow-up. In conclusion, the combination of GP73 and COMP seems efficient to detect cirrhosis and predict worse outcomes and the development of HCC in patients with chronic liver diseases. |
| first_indexed | 2024-03-10T09:43:56Z |
| format | Article |
| id | doaj.art-49fbd2fb70924b938f790c4b43ed151e |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T09:43:56Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-49fbd2fb70924b938f790c4b43ed151e2023-11-22T03:24:27ZengMDPI AGCancers2072-66942021-07-011314351010.3390/cancers13143510Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer?Nikolaos K. Gatselis0Kalliopi Zachou1George Giannoulis2Stella Gabeta3Gary L. Norman4George N. Dalekos5Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, 41110 Larissa, GreeceDepartment of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, 41110 Larissa, GreeceDepartment of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, 41110 Larissa, GreeceDepartment of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, 41110 Larissa, GreeceDepartment of Research and Development, Inova Diagnostics, Inc., San Diego, CA 92131, USADepartment of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, 41110 Larissa, GreeceThe cartilage oligomeric matrix protein (COMP) and Golgi-protein-73 (GP73) have been proposed as markers of liver fibrosis and hepatocellular carcinoma (HCC). Our aim was to assess the performance of the combination of these markers in diagnosing cirrhosis and predicting HCC development. Sera from 288 consecutive patients with chronic liver diseases were investigated by using COMP and GP73-ELISAs. Dual positivity for COMP (>15 U/L) and GP73 (>20 units) was observed in 24 (8.3%) patients, while 30 (10.4%) were GP73(+)/COMP(−), 37/288 (12.8%) GP73(−)/COMP(+), and 197 (68.5%) GP73(−)/COMP(−). Positivity for both markers was associated with cirrhosis [23/24 (95.8%) for GP73(+)/COMP(+) vs. 22/30 (73.3%) for GP73(+)/COMP(−) vs. 25/37 (67.6%) for GP73(−)/COMP(+) vs. 46/197 (23.4%) for GP73(−)/COMP(−); <i>P</i> < 0.001]. The combination of GP73, COMP, the aspartate aminotransferase/platelets ratio index, and the Fibrosis-4 score had even higher diagnostic accuracy to detect the presence of cirrhosis [AUC (95% CI): 0.916 (0.878–0.946)] or significant liver fibrosis (METAVIR ≥ F2) [AUC (95% CI): 0.832 (0.768–0.883)] than each marker alone. Kaplan-Meier analysis showed that positivity for both GP73 and COMP was associated with higher rates of HCC development (<i>P</i> < 0.001) and liver-related deaths (<i>P</i> < 0.001) during follow-up. In conclusion, the combination of GP73 and COMP seems efficient to detect cirrhosis and predict worse outcomes and the development of HCC in patients with chronic liver diseases.https://www.mdpi.com/2072-6694/13/14/3510biomarkercartilage oligomeric matrix proteingolgi protein-73aspartate aminotransferase/platelets ratio index scoreFibrosis-4 scorehepatic fibrosis |
| spellingShingle | Nikolaos K. Gatselis Kalliopi Zachou George Giannoulis Stella Gabeta Gary L. Norman George N. Dalekos Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer? Cancers biomarker cartilage oligomeric matrix protein golgi protein-73 aspartate aminotransferase/platelets ratio index score Fibrosis-4 score hepatic fibrosis |
| title | Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer? |
| title_full | Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer? |
| title_fullStr | Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer? |
| title_full_unstemmed | Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer? |
| title_short | Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer? |
| title_sort | serum cartilage oligomeric matrix protein and golgi protein 73 new diagnostic and predictive tools for liver fibrosis and hepatocellular cancer |
| topic | biomarker cartilage oligomeric matrix protein golgi protein-73 aspartate aminotransferase/platelets ratio index score Fibrosis-4 score hepatic fibrosis |
| url | https://www.mdpi.com/2072-6694/13/14/3510 |
| work_keys_str_mv | AT nikolaoskgatselis serumcartilageoligomericmatrixproteinandgolgiprotein73newdiagnosticandpredictivetoolsforliverfibrosisandhepatocellularcancer AT kalliopizachou serumcartilageoligomericmatrixproteinandgolgiprotein73newdiagnosticandpredictivetoolsforliverfibrosisandhepatocellularcancer AT georgegiannoulis serumcartilageoligomericmatrixproteinandgolgiprotein73newdiagnosticandpredictivetoolsforliverfibrosisandhepatocellularcancer AT stellagabeta serumcartilageoligomericmatrixproteinandgolgiprotein73newdiagnosticandpredictivetoolsforliverfibrosisandhepatocellularcancer AT garylnorman serumcartilageoligomericmatrixproteinandgolgiprotein73newdiagnosticandpredictivetoolsforliverfibrosisandhepatocellularcancer AT georgendalekos serumcartilageoligomericmatrixproteinandgolgiprotein73newdiagnosticandpredictivetoolsforliverfibrosisandhepatocellularcancer |